Scout Bio is a biotechnology company focused on revolutionizing pet medicine by delivering a pipeline of one-time therapeutics for major chronic pet health conditions. Scout has an exclusive research and development collaboration with the University of Pennsylvania's Gene Therapy Program, which has been a global leader in gene therapy research and development for nearly three decades. Scout's therapeutics are designed to induce long-term expression of therapeutic proteins in pet patients using AAV vector technology.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/10/19 | $20,000,000 | Series B |
Adage Capital Management Correlation Ventures Digitalis Ventures  Frazier Healthcare Partners RiverVest Venture Partners | undisclosed |
